glatiramer (Copaxone)
Jump to navigation
Jump to search
Introduction
Tradename: Copaxone. (glatiramer acetate)
Indications
- multiple sclerosis (MS)
- alternative agent for patients unable to tolerate or failure to respond to interferon-beta
Dosage
Monitor
- no monitoring recommended[2]
Adverse effects
- immediate, post-injection site reaction
- lipoatrophy of skin at injection site[2]
- chest pain, palpitations
- flushing (vasodilation)
- anxiety
- transient eosinophilia
- dyspnea
- diaphoresis
- panic attack (rare)[2]
Mechanism of action
- unknown
- polymer of basic amino acids
- reduces relapse rate in patients with relapsing-remitting form of MS
- may delay progression of early multiple sclerosis[4]
Notes
More general terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ 2.0 2.1 2.2 2.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 17. American College of Physicians, Philadelphia 1998, 2015
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 4.0 4.1 Comi G et al, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double- blind, placebo-controlled trial The Lancet, Early Online Publication, 7 October 2009 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19815268 doi:10.1016/S0140-6736(09)61259-9 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2961259-9/abstract
- ↑ 5.0 5.1 Walker J Small Number of Drugs Drive Big Medicare Bill The Wall Street Journal. April 20, 2015 http://www.msn.com/en-us/money/insurance/small-number-of-drugs-drive-big-medicare-bill/ar-BBiZz23
- ↑ 6.0 6.1 Fiore K NeuroBreak: First Copaxone Generic Okayed; Plus for Pain Tx News and commentary from the world of neurology and neuroscience. MedPage Today. October 10, 2017 https://www.medpagetoday.com/Neurology/GeneralNeurology/68443
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis. Sandoz. Feb 13, 2018 https://www.sandoz.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week - ↑ Department of Veterans Affairs, VA National Formulary